drugset / Trial / NCT04003896
A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The prognosis of patients with recurrent, late-stage inoperable, or progressed biliary tract carcinoma (BTC) is generally poor. The goal of this clinical study is to determine the effectiveness and safety of abemaciclib in patients with late-stage or progressed BTC that has failed one line of chemotherapy.
Timeline
- Start
- 2021-09-24
- Primary completion
- 2023-08-15
- Completion
- 2023-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 200 mg | Oral |